MedTrace Logo

Verily Watch Cardio (AF and ECG) Study

NCT06041373 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-12-22

No results posted yet for this study

Summary

This study is designed to evaluate the performance of the Verily Watch Cardio for recording electrocardiogram (ECG) and photoplethysmography (PPG) signals and detecting suspected atrial fibrillation (AF) episodes, in a free-living environment, in participants at risk for having an AF event.

Conditions

Interventions

DEVICE

Verily Watch Cardio

The Verily Watch Cardio is an investigational wrist-worn wearable device containing multiple sensors to measure physiological and environmental metrics, including electrodes that enable a single-lead electrocardiogram (ECG) measurement and a photoplethysmogram (PPG) sensor to monitor for irregular pulses.

DEVICE

iRhythm Zio monitor

The iRhythm Zio monitor, the reference device, is an FDA-cleared single-patient use, continuously recording ECG monitor that can be worn for up to 14 days.

DEVICE

Schiller CARDIOVIT FT-1

The Schiller CARDIOVIT FT-1, the reference device, is an FDA-cleared portable 12-lead ECG machine capable of recording continuous standard 12-lead resting ECG for up to 4 minutes.

Sponsors & Collaborators

  • Verily Life Sciences LLC

    lead INDUSTRY

Principal Investigators

  • Hamid Ghanbari, MD · Verily Life Sciences

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2024-07-31
Completion
2024-11-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06041373 on ClinicalTrials.gov